June 17, 2021
Nearly a third of infants who are hospitalized with a severe form of a common childhood lung infection called bronchiolitis develop asthma a few years later. However, clinicians have been unable to predict which infants with severe bronchiolitis are at high risk for developing asthma and to understand why. Now, a NIAID-funded study published in the journal Nature Communications has taken a step toward accomplishing this.
May 18, 2021
While implementation of highly effective HIV treatment and prevention tools has reduced the HIV pandemic worldwide, development of a safe and even modestly effective vaccine would hasten progress toward a durable end of the HIV pandemic. Today, on HIV Vaccine Awareness Day, NIAID acknowledges both the progress that has been made in HIV vaccine development and the challenges that remain. We also reflect on how advances in HIV vaccinology paved the way for COVID-19 vaccine development.
May 06, 2021
Scientists at NIAID’s Vaccine Research Center and their NIAID-supported colleagues at the University of Washington School of Medicine used tiny nanoparticles to make a huge leap towards the goal of a universal flu vaccine.
April 01, 2021
Single-dose experimental COVID-19 vaccine delivered into the nose of rhesus macaques protected lungs and nasal regions from SARS-CoV-2 infection.
March 24, 2021
On World TB Day, the National Institute of Allergy and Infectious Diseases (NIAID) joins the World Health Organization and others in acknowledging the need for continued, concerted efforts to combat tuberculosis.
March 12, 2021
NIH’s Dr. Carl Dieffenbach joined HIV.gov for a conversation about the latest HIV prevention and treatment research presented there.
March 09, 2021
NIH’s Dr. Carl Dieffenbach shared highlights from HIV research presented at the 2021 virtual Conference on Retroviruses and Opportunistic Infections.
February 09, 2021
NIAID-funded research has expanded the toolbox of medical countermeasures available in case a catastrophic event exposes people to high doses of radiation.
January 29, 2021
An overview of Neglected Tropical Diseases Day and NIAID's long-standing research program devoted to better understanding, treating, and preventing NTDs.
January 14, 2021
By studying the rare disease APECED, NIAID researchers and colleagues uncovered an unexpected immune mechanism that promotes susceptibility to fungal infections of the mucous membranes. Their findings suggest potential therapies for people with APECED and pave the way for work to investigate these tissue-specific immune responses in other diseases.
November 06, 2020
Winners of the 2020 Nobel Prize in Physiology or Medicine included an NIH scientist and a long-time NIAID grantee.
October 23, 2020
A NIAID-sponsored study has shown that short-course antibiotic treatment is superior to standard treatment of community-acquired pneumonia in children.
October 19, 2020
New NIAID-funded research answers longstanding questions about key steps in HIV life cycle.
October 06, 2020
In a study by the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT), researchers investigated the possibility that SARS-CoV-2, the virus that causes COVID-19, could be transmitted to infants through breast milk from mothers who have been infected with SARS-CoV-2. The study enrolled 18 breastfeeding mothers who tested positive for SARS-CoV-2.
September 24, 2020
NIH has awarded approximately $10 million to support implementation science research which aims to reduce new HIV diagnoses in the United States.
September 22, 2020
NIAID Now speaks to Dr. Remais about his research and why a better understanding of the epidemiology of Valley Fever is important.
September 03, 2020
During pregnancy, the mother’s immune system accepts, or tolerates, the presence of the fetus rather than rejecting it as something foreign in the body. This immune tolerance, which dampens the normal maternal immune response, must be carefully balanced with the need to prevent infections from spreading to the placenta and then to the developing fetus.
August 28, 2020
NIAID researchers and their colleagues have developed the first detailed “atlas” of the insect’s immune cells, and discovered a new cell type that may play a role in helping mosquitoes resist infection by malaria-causing parasites. The information contained in this immune atlas may lead to new ways to prevent mosquitoes from transmitting malaria parasites to people.
August 26, 2020
Increasing evidence shows that men tend to have more severe symptoms of COVID-19 and a higher death rate than women with the disease. To investigate whether there are sex-based differences in the body’s immune responses to infection with SARS-CoV-2, the virus that causes COVID-19, a NIAID-funded clinical research study enrolled males and females who were admitted to the hospital with moderate or severe COVID-19.
August 14, 2020
Initial data from a large NIH-supported clinical trial offer a detailed look at the health status of people aging with HIV around the world.
July 23, 2020
HIV remains a major global public health concern. However, effective HIV therapies allow people with HIV to lead long, healthy lives. While these medications can suppress the amount of virus in the blood to a level so low that it is undetectable by standard tests, there are pockets of virus that lie dormant in a small number of cells in the body. These cells, known collectively as the latent HIV reservoir, are not actively producing new virus and therefore can elude the body’s immune system and HIV treatments.
July 20, 2020
NIAID and IAVI, a nonprofit scientific research organization, are collaborating to develop antibody-based products for HIV prevention and treatment.
July 13, 2020
Two new NIAID-supported Zika virus studies reveal potential therapeutic, fetal protection methods.
July 10, 2020
In his final interview with HIV.gov at AIDS 2020: Virtual, NIAID's Dr. Carl Dieffenbach discussed HIV vaccine development, a new partnership to expedite development of HIV antibody combination products, NIH’s engagement in the Ending the HIV Epidemic initiative, and a look to what’s on the horizon in HIV research in the year ahead.
July 09, 2020
Presentations and discussions about the latest HIV research continued at AIDS 2020: Virtual yesterday. HIV.gov shared an interview with Carl Dieffenbach, Ph.D., director of NIAID's Division of AIDS. He discussed additional data from the Tsepamo study on the prevalence of neural tube defects among infants born to women taking the HIV drug dolutegravir at the time of conception, 96-week findings from the South African ADVANCE trial comparing three first-line HIV treatment regimens, and evidence of weight gain caused by different HIV drugs.